Literature DB >> 6350922

Complications in cerebral angiography. A comparison between the non-ionic contrast medium iohexol and meglumine metrizoate (Isopaque Cerebral).

I O Skalpe, I M Anke.   

Abstract

Cerebral angiography was performed in 100 patients in order to study the frequency of adverse effects and complications with a new non-ionic contrast medium, iohexol, compared with an ionic medium, meglumine metrizoate. The study was performed as a double blind clinical trial. Iohexol was better tolerated than meglumine metrizoate, since more patients experienced the injections as painful and unpleasant with metrizoate than with iohexol. However, the subjective adverse effects were minor with both contrast media. There was no statistically significant difference in the frequency of more serious side effects. Transient hemiparesis was seen in two patients who prior to the angiography had suffered from numerous similar attacks per day and in one patient in whom a nearly occluded internal carotid artery was occluded during the examination. These complications occurred in the iohexol group, but are more likely to be due to thromboembolism than to contrast medium toxicity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6350922     DOI: 10.1007/bf00455735

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  9 in total

1.  A radiologic study of the brain circulation by rapid serial angiography of the carotid artery.

Authors:  T GREITZ
Journal:  Acta Radiol Suppl       Date:  1956

2.  Intravascular contrast injection in ischaemic lesions. II. Effect on prognosis.

Authors:  B E Kendall; P Pullicino
Journal:  Neuroradiology       Date:  1980       Impact factor: 2.804

3.  Clinical testing of Amipaque for cerebral angiography.

Authors:  P Amundsen; G Dugstad; M Slettebö
Journal:  Neuroradiology       Date:  1978-04-27       Impact factor: 2.804

4.  Angiography with Amipaque.

Authors:  J T Lamb
Journal:  Neuroradiology       Date:  1978       Impact factor: 2.804

5.  Randomized double-blind cross-over study of iohexol and Amipaque in cerebral angiography.

Authors:  P Amundsen; G Dugstad; J Presthus; K Sveen
Journal:  AJNR Am J Neuroradiol       Date:  1983 May-Jun       Impact factor: 3.825

6.  Complications of cerebral angiography. Comparing metrizamide (Amipaque) and meglumine metrizoate (Isopaque Cerebral).

Authors:  I O Skalpe; A Lundervold; K Tjørstad
Journal:  Neuroradiology       Date:  1980       Impact factor: 2.804

7.  The toxicity of the non-ionic water-soluble contrast media iohexol and metrizamide (Amipaque) in selective vertebral angiography. An experimental study in rabbits.

Authors:  I O Skalpe
Journal:  Neuroradiology       Date:  1981-01       Impact factor: 2.804

8.  Iohexol compared to urografin meglumine in cerebral angiography. A randomized, double blind cross-over study.

Authors:  P Ahlgren
Journal:  Neuroradiology       Date:  1982       Impact factor: 2.804

9.  Cerebral angiography with the non-ionic water-soluble contrast medium iohexol and meglumine-Ca-metrizoate. A randomized double blind parallel study in man.

Authors:  P Nakstad; O Sortland; O Aaserud; A Lundervold
Journal:  Neuroradiology       Date:  1982       Impact factor: 2.804

  9 in total
  3 in total

1.  Complications of cerebral angiography for patients with mild carotid territory ischaemia being considered for carotid endarterectomy.

Authors:  G J Hankey; C P Warlow; A J Molyneux
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-07       Impact factor: 10.154

2.  Contrast enhancement of brain tumors and irradiated normal brain: a comparison of iohexol and iothalamate.

Authors:  J R Fike; C E Cann; K Turowski; D Norman; L Ax
Journal:  Neuroradiology       Date:  1986       Impact factor: 2.804

3.  Complications in cerebral angiography with iohexol (Omnipaque) and meglumine metrizoate (Isopaque cerebral).

Authors:  I O Skalpe
Journal:  Neuroradiology       Date:  1988       Impact factor: 2.804

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.